Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application

被引:115
|
作者
Reinisch, Andreas
Bartmann, Christina
Rohde, Eva
Schallmoser, Katharina
Bjelic-Radisic, Vesna
Lanzer, Gerhard
Linkesch, Werner
Strunk, Dirk
机构
[1] Med Univ, Dept Internal Med, Div Hematol & Stem Cell Transplantat, A-8036 Graz, Austria
[2] Med Univ, Dept Blood Grp Serol & Transfus Med, Graz, Austria
[3] Med Univ, Dept Obstet & Gynaecol, Graz, Austria
关键词
cord blood; good manufacturing practice; mesenchymal stromal cell; transplantation; umbilical cord blood;
D O I
10.2217/17460751.2.4.371
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background: Umbilical cord blood (UCB) is an easily accessible alternative source for multipotent mesenchymal stromal cells (MSCs) and is generally believed to provide MSCs with a higher proliferative potential compared with adult bone marrow. Limitations in cell number and strict dependence of expansion procedures from selected lots of fetal bovine serum have hampered the progress of clinical applications with UCB-derived MSCs. Methods: We analyzed the isolation and proliferative potential of human UCB MSCs compared with bone marrow MSCs under optimized ex vivo culture conditions. We further investigated human platelet lysate as an alternative to replace fetal bovine serum for clinical-scale MSC expansion. Clonogenicity was determined in colony-forming units-fibroblast assays. MSC functions were tested in hematopoiesis support, vascular-like network formation and immune modulation potency assays. Results: MSCs could be propagated from UCB with and without fetal bovine serum. MSC propagation was effective in 46% of UCB samples. Once established, the proliferation kinetics of UCB MSCs did not differ significantly from that of bone marrow MSCs under optimized culture conditions, resulting in more than 50 population doublings after 15 weeks. A clinical quantity of 100 million MSCs with retained differentiation potential could be obtained from UCB MSCs within approximately 7 weeks. Ex vivo expansion of hematopoietic UCB-derived CD34(+) cells as well as immune inhibition and vascular-like network formation could be shown for UCB MSCs propagated under both culture conditions. Conclusion: We demonstrate for the first time that human MSCs can be obtained and propagated to a clinical quantity from UCB in a completely bovine serum-free system. Surprisingly, our data argue against a generally superior proliferative potential of UCB MSCs. Functional data indicate the applicability of clinical-grade UCB MSCs propagated with human platelet lysate-conditioned medium for hematopoiesis support, immune regulation and vascular regeneration.
引用
收藏
页码:371 / 382
页数:12
相关论文
共 50 条
  • [1] Isolation and characterization of equine peripheral blood-derived multipotent mesenchymal stromal cells
    Carvalho, Armando de M.
    Yamada, Ana Lucia M.
    Martins, Juliana R. B.
    Maia, Leandro
    Golim, Marjorie A.
    Deffune, Elenice
    Hussni, Carlos A.
    Alves, Ana Liz G.
    PESQUISA VETERINARIA BRASILEIRA, 2013, 33 (09): : 1151 - 1154
  • [2] ISOLATION AND CHARACTERIZATION OF EQUINE PERIPHERAL BLOOD-DERIVED MULTIPOTENT MESENCHYMAL STROMAL CELLS
    Carvalho, Armando
    Yamada, Ana Lucia
    Golim, Marjorie
    Maia, Leandro
    Martins, Juliana
    Alvarenga, Fernando
    Hussni, Carlos Alberto
    Deffune, Elenice
    Alves, Ana Liz
    EXPERIMENTAL HEMATOLOGY, 2012, 40 (08) : S125 - S126
  • [3] Investigation of in vitro experimental models for immunogenicity assessment of the of cord blood-derived human multipotent mesenchymal stromal cells
    Catenacci, L.
    Moretta, A.
    Cometa, A.
    Lazzari, L.
    Montemurro, T.
    Giordano, R.
    Malinverno, A.
    Travaglino, P.
    Montagna, D.
    Rubert, L.
    Calafiore, L.
    Zecca, M.
    Maccario, R.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S322 - S323
  • [4] Immunological properties of umbilical cord blood-derived mesenchymal stromal cells
    Oh, Wonil
    Kim, Dal-Soo
    Yang, Yoon Sun
    Lee, Jae Kwon
    CELLULAR IMMUNOLOGY, 2008, 251 (02) : 116 - 123
  • [5] Improved isolation protocol for equine cord blood-derived mesenchymal stromal cells
    Koch, Thomas G.
    Thomsen, Preben D.
    Betts, Dean H.
    CYTOTHERAPY, 2009, 11 (04) : 443 - 447
  • [6] Phenotypic and Immunomodulatory Properties of Equine Cord Blood-Derived Mesenchymal Stromal Cells
    Tessier, Laurence
    Bienzle, Dorothee
    Williams, Lynn B.
    Koch, Thomas G.
    PLOS ONE, 2015, 10 (04):
  • [7] Immunomodulatory properties of umbilical cord blood-derived mesenchymal stromal cells expanded in the presence of platelet lysate: potential for clinical application
    Bernardo, M.
    Avanzini, M.
    Perotti, C.
    Cometa, A.
    Zaffaroni, N.
    Novara, F.
    Moretta, A.
    Maccario, R.
    Fibbe, W.
    Locatelli, F.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S160 - S160
  • [8] THE INVOLVEMENT OF MICRORNAS IN EQUINE CORD BLOOD-DERIVED MULTIPOTENT MESENCHYMAL STROMAL CELL'S MONONUCLEAR CELL SUPPRESSIVE POTENCY
    Lee, O.
    Koch, T.
    CYTOTHERAPY, 2018, 20 (05) : E3 - E3
  • [9] Novel clinical uses for cord blood derived mesenchymal stromal cells
    Olson, Amanda L.
    McNiece, Ian K.
    CYTOTHERAPY, 2015, 17 (06) : 796 - 802
  • [10] Human Umbilical Cord Blood-Derived Stromal Cells Are Superior to Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Inducing Myeloid Lineage Differentiation In Vitro
    Sun, Hao-Ping
    Zhang, Xi
    Chen, Xing-Hua
    Zhang, Cheng
    Gao, Lei
    Feng, Yi-Mei
    Peng, Xian-Gui
    Gao, Li
    STEM CELLS AND DEVELOPMENT, 2012, 21 (09) : 1429 - 1440